Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Neuroscience
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human studyTORONTO, Ontario and CAMBRIDGE,...
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce...
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and...
Zeto Exhibits at Neuroscience 2023 and Will Sponsor EEG Clinical Trials
SANTA CLARA, CA / ACCESSWIRE / November 13, 2023 / Zeto, Inc., an innovative EEG brain monitoring company, is excited...
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
New updates designed to advance practice efficiency and patient outcomesMALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
AEON Biopharma Reports Third Quarter 2023 Financial Results
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support...
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered LivesMALVERN, Pa., Nov. 09, 2023 (GLOBE...
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and...
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of...
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on ‘Remarkable People’ Podcast Hosted by Tech Luminary Guy Kawasaki
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal...
New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis
People living with treatment-resistant active psoriatic arthritis reported meaningful improvements in pain, physical function and fatigue on guselkumab through six...
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30...
StageZero Life Sciences’ Clinical Business Introduces Fourth Pillar to Cancer Offerings
Care Oncology Partners with WellnessScript to Offer Mental Health support to cancer patientsTORONTO, ON / ACCESSWIRE / November 7, 2023...
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA
Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access...
Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives
New vice presidents of medical affairs and scientific affairs will support brain health innovationGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the...
Bicycle Health Partners with Override Health to Establish Patient Referral Relationship, Increasing Access to Specialists in Chronic Pain Care and Opioid Use Disorder Treatment
More than one-in-five patients seeking treatment for chronic pain are prescribed opioids at their initial visit, contributing to an opioid...
Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...
New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) -- The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings...